Juno Therapeutics (JUNO) Stock Touches New High

NEW YORK (TheStreet) -- Shares of Juno Therapeutics  (JUNO) surged to a new lifetime high of $56.50 on Monday after the biotech company filed an 8-K form.

The company disclosed in the regulatory filing that it has authorized 495 million shares of new stock. Furthermore, the filing updated the status of the company's license agreement with Opus Bio.

"On December 22, 2014, the conditions to the company's license agreement with Opus Bio, Inc. ('Opus Bio') were satisfied, and the Company's exclusive, worldwide, sublicenseable license under certain patent rights related to a CD22-directed CAR product candidate became effective," the filing states.

Exclusive Report: Jim Cramer’s Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"In connection with the effectiveness of this license, in accordance with the terms previously disclosed in the Registration Statement, the Company paid Opus Bio $20.0 million in cash and issued to Opus Bio 1,602,564 shares of common stock of the Company," it continues.

Juno priced its IPO on December 19 at $24, but the stock has surged above $50 in the days since the offering.

The stock was up 8.7% to $52.97 at 12:03 p.m. More than 6.3 million shares had changed hands by that time.

JUNO Chart JUNO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus